Healthy adult male
Conditions
Interventions
Administer a single oral dose of suspension of DS-1001b containing [14C]DS-1001b to the subjects in the fasted state.
Sponsors
Inoguchi Akihiro
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Subjects who meet all of the following criteria are eligible for the study. 1. Healthy Japanese adult males 2. Aged 18 to 55 years (both inclusive) at the time of informed consent 3. A body mass index (BMI) >=18.5 and <25.0 kg/m^2 at the time of screening test 4. UGT1A1 EM (having no mutation of *6 and *28), or UGT1A1 PM (having either of *6/*6, *6/*28, or *28/*28)
Exclusion criteria
Exclusion criteria: 1. Having a history of stomach or intestinal surgery or disease that would potentially alter absorption and/or excretion of orally administered drugs (however, appendectomy and repair of pyloric stenosis are allowed) 2. Having 3 days or less with at least one spontaneous defecation (bowel movement without purgative medicine, enema or stool extraction) during the 7 days prior to the screening test 3. Having a history of hypersensitivity or being idiosyncratic (e.g., having penicillin allergy) to any drug 4. Underwent administration of radiolabeled substances or exposure to diagnostic/therapeutic radiation (e.g., gastric X ray, computed tomography [CT] scans, positron emission tomography [PET], etc.) during the period from 12 months before study drug administration and until completion of the post-study examination or follow-up examination (however, chest X ray and dental radiography are allowed)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mass balance and pharmacokinetics | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of parent drug and its metabolite, safety | — |
Contacts
Public ContactContact for Clinical Trial Information
Daiichi Sankyo Co., Ltd.
Outcome results
None listed